Glenmark Pharmaceuticals Limited

NSEI:GLENMARK Stock Report

Market Cap: ₹552.5b

Glenmark Pharmaceuticals Past Earnings Performance

Past criteria checks 1/6

Glenmark Pharmaceuticals's earnings have been declining at an average annual rate of -23.1%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 6% per year. Glenmark Pharmaceuticals's return on equity is 11.1%, and it has net margins of 6.5%.

Key information

-23.06%

Earnings growth rate

-23.06%

EPS growth rate

Pharmaceuticals Industry Growth17.49%
Revenue growth rate6.00%
Return on equity11.12%
Net Margin6.45%
Last Earnings Update31 Dec 2025

Recent past performance updates

Glenmark Pharmaceuticals' (NSE:GLENMARK) Earnings Are Weaker Than They Seem

Jun 02
Glenmark Pharmaceuticals' (NSE:GLENMARK) Earnings Are Weaker Than They Seem

Recent updates

Glenmark Pharmaceuticals Limited Just Beat Revenue By 16%: Here's What Analysts Think Will Happen Next

Nov 19
Glenmark Pharmaceuticals Limited Just Beat Revenue By 16%: Here's What Analysts Think Will Happen Next

Getting In Cheap On Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Might Be Difficult

Nov 12
Getting In Cheap On Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Might Be Difficult

Here's Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Is The Least Of Shareholders' Concerns

Sep 20
Here's Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Is The Least Of Shareholders' Concerns

Glenmark Pharmaceuticals (NSE:GLENMARK) Seems To Use Debt Quite Sensibly

Jul 14
Glenmark Pharmaceuticals (NSE:GLENMARK) Seems To Use Debt Quite Sensibly

Investor Optimism Abounds Glenmark Pharmaceuticals Limited (NSE:GLENMARK) But Growth Is Lacking

Jun 23
Investor Optimism Abounds Glenmark Pharmaceuticals Limited (NSE:GLENMARK) But Growth Is Lacking

Glenmark Pharmaceuticals' (NSE:GLENMARK) Earnings Are Weaker Than They Seem

Jun 02
Glenmark Pharmaceuticals' (NSE:GLENMARK) Earnings Are Weaker Than They Seem
User avatar

Lirafit Launch And BeiGene Partnership Set To Accelerate Revenue Growth And Market Share

Upcoming biosimilar launches and strategic oncology partnerships could significantly boost Glenmark's revenue and market share in India.

Revenue & Expenses Breakdown

How Glenmark Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:GLENMARK Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 25165,09710,65140,8630
30 Sep 25159,96610,09840,3340
30 Jun 25133,4207,53730,7440
31 Mar 25133,63310,47136,8140
31 Dec 24139,608-2,00235,8770
30 Sep 24130,799-10,18335,5230
30 Jun 24128,612-15,73228,9730
31 Mar 24126,454-18,99034,4650
31 Dec 23131,575-7,64035,4540
30 Sep 23137,510-1,26334,9980
30 Jun 23136,1442,54628,7400
31 Mar 23116,556-1,69731,8330
31 Dec 22126,3558,81131,7130
30 Sep 22123,4518,30530,0130
30 Jun 22121,1738,27724,8740
31 Mar 22123,0499,41729,1760
31 Dec 21122,10310,20228,7350
30 Sep 21118,24810,46428,8410
30 Jun 21116,14410,22624,3050
31 Mar 21109,4399,70028,1030
31 Dec 20107,7789,56529,3860
30 Sep 20107,4458,99228,9920
30 Jun 20106,6299,20722,7770
31 Mar 20106,5737,76028,6270
31 Dec 19104,3707,17329,4030
30 Sep 19102,5646,42828,8610
30 Jun 19100,2277,68020,9030
31 Mar 1998,6559,25028,7380
31 Dec 1895,5328,86326,6880
30 Sep 1892,0188,72126,3170
30 Jun 1889,0576,71619,4000
31 Mar 1890,7448,03925,1490
31 Dec 1791,9086,42025,1230
30 Sep 1795,05510,08324,4740
30 Jun 1794,89610,23323,7330
31 Mar 1790,7949,16023,6010
31 Dec 1689,31610,40221,4860
30 Sep 1681,7497,50820,9180
30 Jun 1678,4147,29220,0780
31 Mar 1675,7327,02119,2190
31 Dec 1570,3005,69725,6181,624
30 Sep 1569,5305,14125,3351,624
30 Jun 1567,2444,81424,9041,624
31 Mar 1565,5614,75315,4540

Quality Earnings: GLENMARK has a large one-off loss of ₹22.7B impacting its last 12 months of financial results to 31st December, 2025.

Growing Profit Margin: GLENMARK became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: GLENMARK's earnings have declined by 23.1% per year over the past 5 years.

Accelerating Growth: GLENMARK has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: GLENMARK has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.2%).

Return on Equity

High ROE: GLENMARK's Return on Equity (11.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/10 17:55
End of Day Share Price 2026/02/10 00:00
Earnings2025/12/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Glenmark Pharmaceuticals Limited is covered by 42 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited
Ganeshram JayaramanAvendus Spark